Head-to-head evidence
Lerodalcibep vs Tafolecimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Lerodalcibep · Lerochol
Marketed by LIB Therapeutics
NCT04797104 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 478 patients that measured LDL-cholesterol lowering, the standard efficacy measure for this drug class. Lerodalcibep reduced LDL-C by more than half compared with placebo, a highly statistically significant result.
Next expected readout: July 2028 · NCT07102511 (registry estimate)
Tafolecimab · Sintbilo
Marketed by Innovent Biologics
NCT04289285 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial enrolled 804 participants and met its primary endpoint: LDL cholesterol fell by roughly 57 to 65 percentage points more than placebo across both dosing regimens, a highly statistically significant result.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lerodalcibep's landscape · Tafolecimab's landscape